UCLA researchers have engineered AlloCAR70-NKT, a novel allogeneic cell therapy harnessing genetically modified invariant natural killer T cells, to combat metastatic renal cell carcinoma effectively. Demonstrating multi-modal antitumor activity and reprogramming of the tumor microenvironment, this off-the-shelf therapy bypasses the need for patient-specific cell manufacturing. Published in Cell Reports Medicine, the preclinical data underscore its potential to expand accessible immunotherapy options for late-stage kidney cancer patients.